Confronto

Eloralintide vs. Maridebart Cafraglutide

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Metabolico

N. CAS

nessun dato

Peso molecolare

nessun dato

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Eloralintide

Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.

Maridebart Cafraglutide

MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Eloralintide	Maridebart Cafraglutide
Germania	Non approvato	Non approvato
Stati Uniti	Non approvato	Non approvato

Voci complete

Eloralintide

Voce completa →

Maridebart Cafraglutide

Voce completa →

Frequently asked questions

What is the difference between Eloralintide and Maridebart Cafraglutide?: Eloralintide is classified as "Metabolico", while Maridebart Cafraglutide is classified as "Metabolico". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Eloralintide or Maridebart Cafraglutide?: The highest available evidence level is "RCT sull'uomo" for Eloralintide and "RCT sull'uomo" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Eloralintide and Maridebart Cafraglutide in Germany and the United States?: Germania: Eloralintide — Non approvato, Maridebart Cafraglutide — Non approvato. Stati Uniti: Eloralintide — Non approvato, Maridebart Cafraglutide — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

Eloralintide

Maridebart Cafraglutide

Germania

Non approvato

Stati Uniti

Non approvato

Frequently asked questions

What is the difference between Eloralintide and Maridebart Cafraglutide?

Eloralintide is classified as "Metabolico", while Maridebart Cafraglutide is classified as "Metabolico". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Eloralintide or Maridebart Cafraglutide?

The highest available evidence level is "RCT sull'uomo" for Eloralintide and "RCT sull'uomo" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Eloralintide and Maridebart Cafraglutide in Germany and the United States?

Germania: Eloralintide — Non approvato, Maridebart Cafraglutide — Non approvato. Stati Uniti: Eloralintide — Non approvato, Maridebart Cafraglutide — Non approvato. These are factual summaries with source and review date on the individual pages.